AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 83 min read$AQST

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

Original reporting
insidermonkey.com
Published Sep 8, 2026, 4:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$AQSTNeutralMed
01

Why it matters

The cleared studies remove the primary technical barriers identified in the FDA's CRL, positioning the company for a potential expedited review, but approval remains uncertain.

02

Market read

The news provides fresh regulatory‑risk information for a biotech with high short interest, influencing short‑term price dynamics.

03

What to watch

The company's manufacturing contracts (e.g., Suboxone film) provide cash flow that could sustain operations even if Anaphylm is delayed.

Relevance 7/10Novelty 7/10Timing: Q3 2026 FDA resubmission

Background

Aquestive Therapeutics is a micro‑cap biotech focused on an epinephrine film product (Anaphylm) and a broader prodrug platform.

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

Q2 2026 results disclosed a cleared study package and a planned FDA resubmission for the Anaphylm epinephrine film in Q3 2026.

Expected impact

Potential modest upside if FDA accepts the resubmission; downside risk if further delays or rejections occur.

Evidence & confidence

The cleared studies address the FDA's prior CRL concerns, but approval is not guaranteed and cash burn remains significant.

Market effects

Sector

Improves outlook for niche epinephrine delivery platforms and may lift peers in the injectable drug delivery space.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond specialty pharma investors.

Counterpoint

What could challenge this read

Short sellers may argue that repeated FDA setbacks and widening losses outweigh the study clearance, keeping the stock under pressure.

Key entities

  • Company
    Aquestive Therapeutics

    Developer of the Anaphylm epinephrine film and other prodrug products.

  • Regulator
    FDA

    U.S. agency that issued the prior Complete Response Letter and will review the resubmission.

Read at source← All news

Related articles

OCT 16
$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

investing.com2 min
OCT 15
$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.

rttnews.com3 min
OCT 15
$AQSTMedAI 8/10

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027

SEC EDGAR 8-K2 min
OCT 14
$ETONMed

Eton Licenses LIBERVANT For U.S. Seizure Rescue Market

Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) signed an exclusive U.S. licensing agreement for LIBERVANT, a buccal film seizure rescue therapy. Eton gains commercialization rights, while Aquestive will manufacture. The U.S. seizure rescue market is estimated at over $450 million annually. LIBERVANT is expected to launch in April 2027, pending FDA approval. Both companies' stocks showed mixed trading activity.

rttnews.com2 min